Healthcare utilization and medical expenditure of Korean psoriasis patients

Ha, Dongmun; Lee, Jee-Yeon; Kim, Dajeong; Oh, In‐Sun; Lee, Eui-Kyung; Shin, Ju‐Young

doi:10.1097/md.0000000000011070

Cited by 4 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This systematic analysis covered five cost of illness studies in total. From the abovementioned total, two studies were conducted in Southeast Asia, which was in Malaysia Tang et al, 2013); whereas two studies were conducted in Eastern Asia: one in Korea and the other in Japan (Ha et al, 2018;Sruamsiri et al, 2018).…”

Section: Cost Of Illness Study (Coi)mentioning

confidence: 99%

“…Meanwhile, one study was conducted in Southern Asia, which was in India (Satheendran et al, 2016). In terms of study design, two studies were prospective Satheendran et al, 2016) and three studies were retrospective (Ha et al, 2018;Sruamsiri et al, 2018;Tang et al, 2013). All studies were conducted in one-year time horizon.…”

Section: Cost Of Illness Study (Coi)mentioning

confidence: 99%

“…All studies were conducted in one-year time horizon. Three studies included direct and indirect costs Satheendran et al, 2016;Tang et al, 2013), whereas two studies included only direct cost (Ha et al, 2018;Sruamsiri et al, 2018). Two studies calculated costs from both perspectives: patient and provider Tang et al, 2013), two studies measured costs from the insurance payer's perspective (Ha et al, 2018;Sruamsiri et al, 2018) and, and one study calculated cost from the patient's perspective (Satheendran et al, 2016).…”

Section: Cost Of Illness Study (Coi)mentioning

confidence: 99%

“…Three studies included direct and indirect costs Satheendran et al, 2016;Tang et al, 2013), whereas two studies included only direct cost (Ha et al, 2018;Sruamsiri et al, 2018). Two studies calculated costs from both perspectives: patient and provider Tang et al, 2013), two studies measured costs from the insurance payer's perspective (Ha et al, 2018;Sruamsiri et al, 2018) and, and one study calculated cost from the patient's perspective (Satheendran et al, 2016). With regards to the type of treatment, two studies calculated costs associated with biologics Sruamsiri et al, 2018), three studies measured costs associated with systemic (methotrexate) and phototherapy (psoralen-UVA or PUVA and narrowband UVB) treatments Satheendran et al, 2016;Tang et al, 2013).…”

Section: Cost Of Illness Study (Coi)mentioning

confidence: 99%

See 3 more Smart Citations

Economic Burden and Cost-Effectiveness of Moderate to Severe Psoriasis Treatment in Asian Region: A Systematic Review

Rismayuddin

Azizam

Ismail

2021

ABRIJ

View full text Add to dashboard Cite

Psoriasis poses a significant economic burden. A systematic review of psoriasis treatments cost and effectiveness has been performed extensively in the United States (US) and Europe, but such review is limited in Asia. This review aims to analyze all previous literature on the cost and effectiveness of systemic and biological treatment for moderate to severe psoriasis. Cost of illness and cost-effectiveness studies that examined the economic burden, cost, and effectiveness of psoriasis treatments (systemic and biological) in Asian region from 2010 to 2020 were published in English language. All costs were converted into 2020 US Dollar. All COIs included found that direct medical costs were greater than indirect costs. Adalimumab, ustekinumab, risankizumab, secukinumab 150 mg were cost-effective treatments and of the lowest cost per PASI-75/PASI1 and/or QALY. When comparing the different treatments, topical and systemic psoriasis treatments were observed to be the most cost-effective compared with other modalities. Given the tremendous economic effects of psoriasis on patients and hospitals, economic analysis, clinicians, and policymakers should consider cost and effectiveness evidence, as this systematic literature review was conducted to analyze previous documentation regarding the cost and effectiveness of systemics and biologics in Asian countries.

show abstract

Section: Cost Of Illness Study (Coi)mentioning

confidence: 99%

Section: Cost Of Illness Study (Coi)mentioning

confidence: 99%

Section: Cost Of Illness Study (Coi)mentioning

confidence: 99%

Section: Cost Of Illness Study (Coi)mentioning

confidence: 99%

See 2 more Smart Citations

Economic Burden and Cost-Effectiveness of Moderate to Severe Psoriasis Treatment in Asian Region: A Systematic Review

Rismayuddin

Azizam

Ismail

2021

ABRIJ

View full text Add to dashboard Cite

show abstract

“…[ 13 ] Nonetheless, psoriasis treatment remains a cause for huge economic burden for many patients with severe psoriasis. [ 14 ]…”

Section: Introductionmentioning

confidence: 99%

Differential characteristics and treatment of psoriasis patients by economic status in South Korea

Ryu

Chun

et al. 2020

Medicine

Self Cite

View full text Add to dashboard Cite

Despite the enormous burden on patients with severe psoriasis, their utilization of medical care is not well understood in Korea. To compare the characteristics and treatment patterns of psoriasis patients by economic status as well as to examine the factors influencing systemic treatments of psoriasis. We conducted a descriptive cross-sectional study using National Health Insurance sample cohort data in 2015. Psoriasis patients were classified as either the “topical treatment only” or the “systemic treatment” group based on the types of treatment. Patients’ economic status was defined by the deciles of health insurance premium, which was determined based on income and assets. Multivariate logistic regression analysis was performed to examine the factors influencing systemic treatments of psoriasis. We identified 6041 psoriasis patients; 39.5% were in the bottom 5 deciles of health insurance premium and 60.5% were in the top 5 deciles. Only 1.9% of the low economic status group and 4.0% of the high economic status group were treated with expensive biologics, although the difference was not statistically significant. Overall, psoriasis patients with higher economic status had a lower likelihood of receiving systemic treatments but had a higher probability of being treated with expensive biologics.

show abstract

Uncovering the unmet needs among psoriasis patients in the Asia‐Pacific region

Tada

Huang

et al. 2021

The Journal of Dermatology

View full text Add to dashboard Cite

Studies on the psychosocial and emotional burden of psoriasis have been extensive; however, there is limited knowledge and awareness of patients’ attitude and behavior towards psoriasis treatment. To understand psoriasis patients’ attitude and behavior towards treatment of psoriasis, especially those treated with biologics, a multi‐stage study qualitative and quantitative methodology was conducted among psoriasis patients. An online survey was conducted with 45 moderate‐to‐severe psoriasis patients each in Australia, Japan, South Korea, and Taiwan for 20 min. This was followed by qualitative in‐depth interviews conducted among psoriasis patients in Australia (n = 3) and Japan (n = 2) for 60 min. All of the findings were workshopped with key opinion leaders and patient advisory groups to identify potential solutions addressing patients’ unmet needs. Five common insights were identified across the region, highlighting patients’ attitude and behavior towards psoriasis treatment, especially for those treated with biologics. These insights comprised the following: (i) one of the key factors driving patients’ treatment choice included their ability to enjoy clear skin for longer period (68%); (ii) bio‐maintenance patients had a higher expectation (4.9 months) of how long their skin could stay clear, compared to their pre‐biologics initiation days (2.9 months); (iii) once a good response is achieved, bio‐maintenance patients were more concerned about symptoms returning (44%) than development of side‐effects (19%); (iv) bio‐maintenance patients felt psychologically and physically affected during flare‐ups despite being on more efficacious treatment; and (v) bio‐maintenance patients still felt they were at risk of flare‐ups (4.5/7), almost similar risk perception as non‐biologics patients (4.9/7). Findings from this study showed that psoriasis patients look for treatment with the least risk of flare‐ups so that they were able to enjoy clear skin for a long time.

show abstract

Healthcare utilization and medical expenditure of Korean psoriasis patients

Abstract: Supplemental Digital Content is available in the text

Cited by 4 publications

References 20 publications

Economic Burden and Cost-Effectiveness of Moderate to Severe Psoriasis Treatment in Asian Region: A Systematic Review

Economic Burden and Cost-Effectiveness of Moderate to Severe Psoriasis Treatment in Asian Region: A Systematic Review

Differential characteristics and treatment of psoriasis patients by economic status in South Korea

Uncovering the unmet needs among psoriasis patients in the Asia‐Pacific region

Contact Info

Product

Resources

About